Research map: Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B ‐cell acute lymphoblastic leukemia: A report from The Cytometry Society, India

Back to the article

Papers in this map

  1. Delphi Technique in Health Sciences: A Map · Marlen Niederberger · 2020 · 1106 citations · Cited by this paper
  2. Therapy‐related B ‐lymphoblastic leukemia/lymphoma with MYC rearrangement and multisite involvement following chemotherapy for ovarian cancer · 2026 · Related
  3. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols · Tomáš Kalina · 2012 · 795 citations · Cited by this paper
  4. Bridging the implementation gap in AI ‐assisted flow cytometry · 2025 · Related
  5. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party · Michael Heuser · 2021 · 774 citations · Cited by this paper
  6. Comment on “An unusual pattern observed upon the addition of CD79b to a flow‐Cytometry B‐cell Lymphoma panel” ( Cytometry B Clin Cytom. 2025 Jul 14. Doi: 10.1002/cyto.b.22246. Epub ahead of print. PMID : 40657818) · 2025 · Related
  7. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma · Juan A Flores-Montero · 2017 · 681 citations · Cited by this paper
  8. Detailed analysis of TRBC1 distribution in T‐cell subsets and its application in T‐cell clonality assessment · 2026 · Related
  9. The Use of the Delphi and Other Consensus Group Methods in Medical Education Research: A Review · Susan M. Humphrey-Murto · 2017 · 639 citations · Cited by this paper
  10. Signal without noise: Practical antibody titration for platelet flow cytometry · 2025 · Related
  11. Antibody validation · Jennifer Bordeaux · 2010 · 607 citations · Cited by this paper
  12. Coexistent dual CD4 +/ CD8− and CD4− / CD8 + T‐cell large granular lymphocytic leukemia in a young adult male: An exceedingly rare finding · 2025 · Related
  13. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) · Andrea Cossarizza · 2021 · 520 citations · Cited by this paper
  14. Automated B ‐cell and plasma cell identification using unsupervised clustering by FlowSOM and an excel‐based classification model · 2026 · Related
  15. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies · Jacques J. M. van Dongen · 2015 · 514 citations · Cited by this paper
  16. Issue highlights—July 2026 · 2026 · Related
  17. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia · Prisca M. J. Theunissen · 2016 · 437 citations · Cited by this paper
  18. Flow cytometry‐based monitoring of chimeric antigen receptor ( CAR ) T cells: Reagent selection, assay design, and clinical utility · 2026 · Related
  19. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 · Michael J. Borowitz · 2015 · 365 citations · Cited by this paper
  20. Issue Highlights—March 2026 · 2026 · Related
  21. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia · Michael Norbert Dworzak · 2002 · 328 citations · Cited by this paper
  22. New markers for minimal residual disease detection in acute lymphoblastic leukemia · Elaine Coustan‐Smith · 2011 · 326 citations · Cited by this paper
  23. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases · Sara Raponi · 2011 · 229 citations · Cited by this paper
  24. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting · Maria Jorge Arroz · 2015 · 194 citations · Cited by this paper
  25. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry · Brent Lee Wood · 2015 · 165 citations · Cited by this paper
  26. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible · Michael Norbert Dworzak · 2008 · 157 citations · Cited by this paper
  27. AIEOP ‐ BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia · Michael Norbert Dworzak · 2017 · 155 citations · Cited by this paper
  28. Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia · Dario Campana · 2017 · 150 citations · Cited by this paper
  29. Quality assessment program for E uro F low protocols: Summary results of four‐year (2010–2013) quality assurance rounds · Tomáš Kalina · 2014 · 141 citations · Cited by this paper
  30. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition · Maryalice Stetler‐Stevenson · 2015 · 139 citations · Cited by this paper
  31. Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design · Richard Nguyen · 2013 · 138 citations · Cited by this paper
  32. A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy · Sindhu Cherian · 2016 · 113 citations · Cited by this paper
  33. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses · Michael R. Loken · 2008 · 104 citations · Cited by this paper
  34. Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms · Ulrika Johansson · 2014 · 98 citations · Cited by this paper
  35. Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research · Annieck M. Diks · 2019 · 94 citations · Cited by this paper
  36. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities · Xueyan Chen · 2016 · 92 citations · Cited by this paper
  37. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party · Jesse M. Tettero · 2021 · 92 citations · Cited by this paper
  38. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL · Sara Ghorashian · 2023 · 92 citations · Cited by this paper
  39. Validation of cell‐based fluorescence assays: practice guidelines from the ICSH and ICCS – part II – preanalytical issues · Bruce H. Davis · 2013 · 90 citations · Cited by this paper

Source: OpenAlex (CC0)